文献速递青光眼小儿眼科与斜弱视

新型微分流管用于难治性儿童青光眼的初步经验:一项同情用药/早期准入队列研究

Use of a Novel Microshunt in Refractory Childhood Glaucoma: Initial Experience in a Compassionate Use/Early Access Cohort.
PubMed 文献 · Am J Ophthalmol · 2022-03-26

这项前瞻性单中心病例系列在FDA同情用药器械豁免下,对12例难治性儿童青光眼患者(15个月至14岁)植入新型聚合物微分流管,术前平均眼压22.72±4.8 mmHg、使用3.3±0.65种降眼压药物。随访≥1年的患眼中9眼控制成功,术前眼压21.6±4.9 mmHg在1年时下降45%至11.9±3.8 mmHg,7例患者12个月时未用药,3眼失败需再次手术。作者认为早期数据提示该装置安全且似乎有效,并计划开展前瞻性多中心关键性试验。

要点

  • 12眼(12例儿童)植入微分流管,术中无并发症。
  • 随访≥1年者9眼成功控制,术前眼压21.6±4.9 mmHg降至1年11.9±3.8 mmHg(降45%)。
  • 12个月时7例未用药、2例需2种药物(多佐胺-噻吗洛尔固定复方),3眼失败再手术。

核心结论

  • 这些早期数据提示该装置在难治性儿童青光眼患者中安全且似乎有效。
  • 计划开展前瞻性多中心关键性试验。

研究设计与样本

  • 前瞻性单中心病例系列,在FDA同情用药研究性器械豁免下经FDA和机构审查委员会批准,最多治疗20例儿童。
  • 对难治性儿童青光眼患者的单眼行微分流管手术,报告随访≥1年的患者。
  • 共12眼(12例儿童),年龄15个月至14岁,自2019年12月开始治疗。

主要发现

  • 术前平均眼压22.72±4.8 mmHg,使用3.3±0.65种降眼压药物。
  • 术中无并发症发生。
  • 随访≥1年(范围12-23个月)的患眼中9眼成功控制。
  • 该组术前眼压21.6±4.9 mmHg在1年时下降45%至11.9±3.8 mmHg。
  • 12个月时7例患者未使用药物,2例需2种药物(多佐胺-噻吗洛尔固定复方);3眼失败需额外手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In patients with refractory childhood glaucoma, treatment options include trabeculectomy or large glaucoma drainage devices (GDDs) with attendant short- and long-term risks. A novel polymer-based microshunt is under review by the US Food and Drug Administration (FDA) for use in adults. The device is attractive for children given the long-term stability of the polymer and the small conjunctival incision required for implantation. This early clinical series explores the safety and efficacy of this device in patients with refractory childhood glaucoma who would otherwise undergo trabeculectomy or implantation of a GDD. DESIGN: Prospective single-center case series under FDA compassionate use investigational device exemption. METHODS: FDA and institutional review board approvals were obtained to treat ≤20 children using this investigational device under the compassionate use pathway. Single eyes in patients with refractory childhood glaucoma were treated surgically with the microshunt. Patients with ≥1 year of follow-up are reported. RESULTS: Twelve eyes of 12 children (15 months to 14 years if age) with mean preoperative intraocular pressure of 22.72 ± 4.8 mm Hg on 3.3 ± 0.65 medications were treated beginning in December 2019. No intraoperative complications occurred. Among eyes with ≥1 year of follow-up (range 12-23 months), 9 were successfully controlled. In this group, preoperative intraocular pressure 21.6 ± 4.9 mm Hg dropped 45% to 11.9 ± 3.8 mm Hg at 1 year; 7 patients were taking no medications at 12 months, and 2 required 2 medications (fixed-combination dorzolamide-timolol). Three eyes failed, requiring additional surgery. CONCLUSION: These early data suggest that the device is safe and appears effective in patients with refractory childhood glaucoma. A prospective, multicenter pivotal trial is planned.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Brandt JD. Use of a Novel Microshunt in Refractory Childhood Glaucoma: Initial Experience in a Compassionate Use/Early Access Cohort. Am J Ophthalmol. 2022. PMID: 35346624. doi:10.1016/j.ajo.2022.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。